IND clearance marks the first ever cellular rejuvenation therapy using partial epigenetic reprogramming to reach human clinical trials BOSTON, January 28, 2026 – Life Biosciences, Inc., (“Life Bio”) a...

This is the channel for the Aging Research and Drug Discovery meeting (www.agingpharma.org). We reserve the right to remove derogatory, personal and/or non-scientific comments.

BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies Growing preclinical and cli...

The FDA recently accepted the Target Animal Safety (TAS) submission for LOY-002, our drug in development for senior dog lifespan extension. Our Director of Veterinmary Medicine, Brennen McKenzie, expl...

13 years after the first 'aging clock' was published we're still measuring mouse lifespan and unable to run human aging trials. What's missing?

The Advanced Research Projects Agency for Health (ARPA-H) supports transformative research to drive biomedical and health breakthroughs ranging from molecular to societal to provide transformative hea...

Learn how longevity science could help us all live healthier for longer—and what extending healthspan means for policy, ageing, and the economy.

In January, AbbVie and Calico’s fosigotifator failed to show significant signs of efficacy in the HEALEY ALS platform trial for amyotrophic lateral sclerosis.

In cross-sectional and longitudinal analyses of 86,149 participants across 27 European countries, Amoruso, Hernandez and colleagues identify multilingualism as a protective factor against accelerated ...

BACKGROUND Danish women vaccinated with the 4-valent human papillomavirus (HPV) vaccine (HPV types: 6/11/16/18) at age 14 in 2008 reached screening age in 2017, allowing assessment of long-term effects on prevalence, persistence and incidence of HPV infections. AIM To examine the HPV status of cervical samples over time among women vaccinated as girls. METHODS Between February 2017 and February 2024, residual material from cytology-analysed samples collected through the ‘Trial23’ study, part of the national screening programme, was tested for HPV16/18 and non-vaccine high-risk (HR) HPV types. Prevalence in first, second and third samples, and persistence and incidence between samples were calculated. RESULTS Over 7 years, 8,659 women provided at least one sample, 5,835 at least two and 2,461 at least three. In 7,800 vaccinated women, HPV16/18 prevalence was 0.4% (95% confidence interval (CI): 0.2–0.5), 0.3% (95% CI: 0.1–0.4) and 0.2% (95% CI: 0.0–0.4) in three consecutive samples. Prevalence of non-vaccine HR HPV was 32% (95% CI: 31–33), 28% (95% CI: 27–29) and 31% (95% CI: 29–33). Persistence of HPV16/18 and non-vaccine HPV among vaccinated women was 40% and 53%. In adjusted analyses comparing vaccinated vs unvaccinated women, incidence was significantly lower for HPV16/18 (adjusted relative risk (aRR) < 0.10) while incidence of non-vaccine HR HPV types was higher (aRR: 1.66; 95% CI: 1.12–2.45). No significant difference was observed for persistence. CONCLUSION Our study provides real-world evidence of stable protection against HPV16/18 infections in women vaccinated as girls. Less intensive screening seems reasonable until women vaccinated with the 9-valent vaccine reach screening age, when screening should be reconsidered.

A4LI Scientist Spotlight · Episode

A4LI Scientist Spotlight · Episode

Authorities are investigating why two women fell ill at the Revolution Against Aging and Death Festival. They both received peptide injections, an alternative therapy promoted by Robert F. Kennedy Jr....

Grading the giants on their race to extend human healthspan